article
Spatial biology is the next life science revolution
Dr Richard Goodwin, Head of Imaging & AI, Clinical Pharmacology & Safety Sciences at AstraZeneca, explores the latest innovation in early therapeutic development – spatial biology.
List view / Grid view
Imaging, sequencing & screening
news
Collaborative research efforts enabled rapid response to Omicron variant
News from the Pasteur Institute in France reports on how multi organisational efforts of numerous research institutes enabled the scientific community to gain key insight into the Omicron variant, facilitating a rapid life-saving response.
article
Advancing neutralising antibody therapies for COVID-19
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
article
SARS-CoV-2 and immunology: antibody developments
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
news
Deletions in SARS-CoV-2 Spike protein drive antibody escape, study shows
Researchers have found that SARS-CoV-2 evades immune responses by deleting parts of its genetic sequence that encode for the Spike protein.
news
COVID-19 vaccine candidate stimulates neutralising antibody production in vivo
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
news
Majority retain COVID-19 antibodies for six months after infection
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
news
Novel AI tool takes a DeepCE dive into potential drugs for COVID-19
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
news
N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
news
UK offers genomics expertise to identify new SARS-CoV-2 variants
The UK Government has said genomics expertise will be offered to countries around the world to identify new variants of SARS-CoV-2.
news
T cells target broad range of SARS-CoV-2 epitopes, study shows
A study has found that T cells combat SARS-CoV-2 by targeting many sites on the coronavirus, not just the Spike protein.
news
New database to track neurological symptoms of COVID-19
NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
news
Biomarker in blood could determine severity of COVID-19
A study has shown that patients with severe COVID-19 have significantly elevated levels of M-MDSCs in their blood compared with healthy individuals.
news
Novel antibody candidate could offer pan-coronavirus protection
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
news
Rhesus macaques with SARS-CoV-2 develop promising immune response
A study has shown that the immune response of rhesus macaques with SARS-CoV-2 could be reproduced with a vaccine.
